Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.41 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31365208 | 1.00 | CYP2B6 (0.41) | CYP2B6TENT4ATENT4B | |
| SCHEMBL31365220 | 0.89 | CYP2B6 (0.33) | CYP2B6TENT4ATENT4B | |
| SCHEMBL27200121 | 0.89 | CYP2B6 (0.33) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22898887 | 0.85 | CYP2B6 (0.52) | CYP2B6TENT4ATENT4B | |
| SCHEMBL31365231 | 0.85 | CYP2B6 (0.52) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22898996 | 0.84 | CYP2B6 (0.46) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22898918 | 0.83 | CYP2B6 (0.45) | CYP2B6TENT4ATENT4B | |
| SCHEMBL31365217 | 0.83 | CYP2B6 (0.33) | CYP2B6TENT4ATENT4B | |
| SCHEMBL27200093 | 0.83 | CYP2B6 (0.33) | CYP2B6TENT4ATENT4B | |
| SCHEMBL31365199 | 0.80 | CYP2B6 (0.41) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | REJUVERON TELOMERE THERAPEUTICS AG (CH) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | DPP9, DPYD, QDPR | CYP2B6 26/4885TENT4A 2925/4885TENT4B 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.